Catherine C. Coombs, MD

Catherine C. Coombs, MD, is a hematologist-oncologist and associate clinical professor in the Department of Medicine of the Division of Hematology/Oncology at University of California Irvine Health.

Articles

Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

July 9th 2024

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.

Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

July 8th 2024

The panelists explore strategies for managing front-line chronic lymphocytic leukemia (CLL) treatment in patients with pre-existing hypertension and atrial fibrillation.

Frontline BTKi Selection

July 8th 2024

Key opinion leaders examine the use of continuous Bruton's tyrosine kinase inhibitor therapy in front-line treatment, strategies for sequencing therapies, and the potential incorporation of obinutuzumab into treatment regimens.

Implications of Real-World Data in the 1L Treatment of High-Risk CLL

July 3rd 2024

Catherine C. Coombs, MD, discusses the value of real-world data in informing the treatment of patients with chronic lymphocytic leukemia.

Navigating Continuous BTKi Therapy for CLL in the 1L Setting

July 3rd 2024

John N. Allan, MD, describes how he selects patients for first-line treatment with continuous BTK inhibitor therapy, referencing data from the RESONATE-2, ELEVATE-TN, and SEQUOIA studies.

Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL

June 27th 2024

Leading chronic lymphocytic leukemia specialists explore strategies for selecting initial treatments, weighing the merits of fixed-duration versus continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy for newly diagnosed patients.

Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024

June 27th 2024

Key opinion leaders are introduced and present a concise overview of the topics to be addressed.

Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

June 25th 2024

Bita Fakhri, MD, MPH, outlines factors she considers when choosing between fixed-duration and continuous BTK inhibitor therapy and discusses how she approaches treatment discussions with patients.

Patient with Newly Diagnosed CLL with High-Risk Features

June 25th 2024

A panel of experts on chronic lymphocytic leukemia (CLL) review a patient case and describe their initial impressions on treatment decisions.

Dr Coombs on the Ongoing Investigation of Quizartinib in AML

April 22nd 2024

Catherine C. Coombs, MD, discusses the efficacy of the FLT3 inhibitor quizartinib in acute myeloid leukemia.

Dr Coombs on Disease Management Strategies in AML

April 18th 2024

Catherine C. Coombs, MD, discusses strategies for disease classification and management for patients with acute myeloid leukemia.

Dr Coombs on Noncovalent BTK Inhibitors in Relapsed/Refractory MCL

April 5th 2024

Catherine C. Coombs, MD, discusses the mechanism of action of noncovalent BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Future Perspectives on the Treatment Landscape for CLL

February 16th 2024

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.

Expert Insights into Investigation Therapies for CLL

February 16th 2024

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

February 9th 2024

The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.

Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials

February 9th 2024

Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.

Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice

February 2nd 2024

Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.

Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

February 2nd 2024

A panel of expert oncologists explore the influence of hypertension risk and other cardiovascular AEs in guiding treatment selection with BTKis, sharing insights from ASH 2023.

Expert Perspectives on Navigating Treatment Selection with BTKis in CLL

January 26th 2024

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE

January 26th 2024

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.